title: Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol.
authors.forename: Bruce J
authors.initials: BJ
authors.lastname: Kinon
authors.forename: Sara
authors.initials: S
authors.lastname: Kollack-Walker
authors.forename: Virginia
authors.initials: V
authors.lastname: Stauffer
authors.forename: Hong
authors.initials: H
authors.lastname: Liu-Seifert
mesh_terms: D000328:Adult; D000368:Aged; D017109:Akathisia, Drug-Induced / Q000503:physiopathology / Q000517:prevention & control*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D010054:Brief Psychiatric Rating Scale; D016903:Drug Monitoring; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D000077152:Olanzapine; D011618:Psychotic Disorders / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012559:Schizophrenia / Q000188:drug therapy; D012720:Severity of Illness Index; D013997:Time Factors; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D006220:Haloperidol; D000077152:Olanzapine